Overview

Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of vorolanib combined with cadonilimab in the treatment of untreated advanced RCC patients.
Phase:
PHASE1
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
vorolanib